As sports grapples with the effects of injuries, one area of medicine is looking to make pain and recovery a thing of the past.» Read More
An intestinal illness called Shigellosis and carried by international travelers is spreading across the U.S., according to the Centers for Disease Control and Prevention.
CNBC's Meg Tirrell takes a deeper look at Autism, the people it affects and where treatment stands.
Merrimack CEO Bob Mulroy joins CNBC's Meg Tirrell to discuss the Merrimack development pipeline for nanotherapeutic chemotherapy.
Sam Isaly, OrbiMed Advisors managing partner, says valuations are more than they used to be but adds, they're not crazy, they're sensible. He shares his view of the biotech sector.
As gene therapy emerges in the biotech industry, one analyst explains why it could be the next billion dollar industry.
Andrew Morey, portfolio manager at ASTON LMCG Small Cap Growth Fund, attributes the rally in U.S. biotech shares to "fundamental merits" like clinical advances.
A national pharmacists' group has adopted a policy discouraging its members from providing death-penalty drugs.
CNBC's Meg Tirrell reports on health care consolidation and PBM stocks to watch.
CNBC's Bertha Coombs reports on healthcare stock deals including Catamaran to be acquired by UnitedHealth for $12.8B.
Jamie Dinan, York Capital founder and CEO, discusses some of his firm's top stock picks. Among the names, he likes the Kraft Foods Group-Heinz deal, as well as McDonald's, which he says is now in the "show me" category.
Jamie Dinan, York Capital founder and CEO, discusses the advancements in biotechnology, and high stock valuations. He says shorting the biotech ETF can be dangerous.
Teva Pharmaceutical is buying Auspex Pharmaceuticals, reports CNBC's Joe Kernen.
After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
After speaking with the Genfit CEO, CNBC's Meg Tirrell discusses the company's future and the potential opportunity.
For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Eric Schmidt, Cowen & Company analyst, provides perspective on the biotech space after the Nasdaq biotech index posted its worst daily drop since December.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
"Fast Money" traders discussed how to play Wednesday's selloff in biotech, transportation and technology names.
Get the best of CNBC in your inbox